A single-arm, open-label, phase 2 study of MGAH22 (margetuximab) [fc-optimized chimeric anti-HER2 monoclonal antibody (mAb)] in patients with relapsed or refractory advanced breast cancer whose tumors express HER2 at the 2+ level by immunohistochemistry and lack evidence of HER2 gene amplification by FISH.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Stanford University, Florida Cancer Care, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Sarah Cannon, Tennessee Oncology, MacroGenics (United States), Tufts Medical Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2280869417